NEWS & MEDIA
ENDPOINT NEWS
4 MARCH 2024
Exclusive: Nocion raises $62M for different approach to chronic cough than Merck, GSK
ENDPOINT NEWS
4 JANUARY 2024
ARCH-backed immunology company HI-Bio raises $95M as it pushes toward late-stage studies
GlobeNewswire
16 AUGUST 2022
Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis
GlobeNewswire
29 APRIL 2021
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
Business Wire
April 15 2020
UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer
Intrado GlobeNewswire
11 March 2020
Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs
Intrado GlobeNewswire
11 March 2020
Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs
Business Wire
9 MARCH 2020
Arkin Holdings Raises $140 Million in Second Partnership Arkin Bio-Ventures II to Invest in Groundbreaking Pharma and Biotechnology Companies
CISION PR NEWSWIRE
30 JULY 2018
BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
CISION PR NEWSWIRE
12 MARCH 2018
Cogentix Medical Enters Definitive Merger Agreement to be Acquired by Laborie Medical Technologies for a Purchase Price of $3.85 Per Share in Cash
NASDAQ GLOBE NEWSWIRE
05 FEBRUARY 2018
Sol-Gel Technologies Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NASDAQ GLOBE NEWSWIRE
5 JANUARY 2018
Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)
YAHOO FINANCE
14 DECEMBER 2017
BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia
PR NEWSWIRE
16 MAY 2016
Arkin Holdings and Primera Capital Lead an Investment of $13M in BioSight for an Innovative Treatment of Acute Leukemia